A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Cardiovascular disorders; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms CLEAR Outcomes; CVOT
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 20 Feb 2018 According to an Esperion Therapeutics media release, top-line results from this study are expected to support the submissions for a cardiovascular disease risk reduction indication in the U.S. and Europe by 2022.
    • 20 Feb 2018 According to an Esperion Therapeutics media release, patient enrollment is proceeding as planned and remains on track to fully enroll by mid-2019.
    • 20 Mar 2017 According to an Esperion Therapeutics media release, this trial is on track to be well-underway by 1H 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top